The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Globe Investor

News Sources

Take control of your investments with the latest investing news and analysis

Press release from Business Wire

Illumina to Announce Second Quarter 2011 Financial Results on Tuesday, July 26, 2011

Tuesday, July 12, 2011

Illumina to Announce Second Quarter 2011 Financial Results on Tuesday, July 26, 201106:00 EDT Tuesday, July 12, 2011 SAN DIEGO (Business Wire) -- Illumina, Inc. (NASDAQ:ILMN) today announced that it will issue results for second quarter 2011 following the close of market on Tuesday, July 26, 2011. On the same day, at 1:30 pm Pacific Time (4:30 pm Eastern Time) Jay Flatley, President and Chief Executive Officer, and Christian Henry, Senior Vice President, Chief Financial Officer, and General Manager, Life Sciences, will host a conference call with analysts, investors, and other interested parties to discuss financial and operating results. Conference Call Details The conference call will begin at 1:30 pm Pacific Time (4:30 pm Eastern Time) on Tuesday, July 26, 2011. Interested parties may listen to the call by dialing 866.770.7146 (passcode: 43976139), or if outside North America, by dialing +1.617.213.8068 (passcode: 43976139). Individuals may access the live teleconference in the Investor Relations section of Illumina's web site under the “Company” tab at www.illumina.com. A replay of the conference call will be available from 4:30 pm Pacific Time (7:30 pm Eastern Time) on July 26, 2011 through August 2, 2011 by dialing 888.286.8010 (passcode: 20537846), or if outside North America, by dialing +1.617.801.6888 (passcode: 20537846). About Illumina Illumina (www.illumina.com) is a leading developer, manufacturer, and marketer of life science tools and integrated systems for the analysis of genetic variation and function. We provide innovative sequencing and array-based solutions for genotyping, copy number variation analysis, methylation studies, gene expression profiling, and low-multiplex analysis of DNA, RNA and protein. We also provide tools and services that are fueling advances in consumer genomics and diagnostics. Our technology and products accelerate genetic analysis research and its application, paving the way for molecular medicine and ultimately transforming healthcare. Illumina, Inc.Investors:Kevin Williams, MD, Investor Relations858-332-4989kwilliams@illumina.comorMedia:Laura Trotter, Public Relations858-822-6822pr@illumina.com